Interview with Dr. John R. Thornback, Chief Executive Officer, Dx assays
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
Address: Unit #02-01/02/03, Blk 35 Marsiling Ind Estate Road 3, Woodlands Central Industrial Estate, Singapore 739257,Singapore
Tel: +65 6499 0720
Dx assays mission is to provide high-quality molecular assay development and assay validation to their customers with speed and efficiency, coupled with their fee-for-service and co-development business model, Dx assays focus on ‘delivering your success’.
Their laboratories are equipped with the state-of-the-art technologies and are operated by highly qualified personnel according to CE and FDA requirements. They provide fully ISO 9001 and ISO 13485 accredited processes and procedures which gives its clients a guarantee of high quality product development and documentation that meets regulatory requirements
Dx assays provide advanced molecular diagnostic assay development, verification, validation, and high quality product enhancement services. They have a proven track record and have delivered successful projects to a wide variety of pharmaceutical, clinical and diagnostic customers all around the world.
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
What is the global R&D vision of Takeda, Japan’s largest pharmaceutical company that recently celebrated its 230th birthday? Takeda’s global R&D vision is committed to the discovery and development of…
What prompted you to found TriReme six years ago? I set up companies, so TriReme was not the first. The idea behind TriReme was to provide solutions for complex cases,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Since the last time we had the pleasure of meeting you, 4 years ago, what have been the main developments and changes in the Singaporean pharmaceutical industry? One of the…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put…
There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years?…
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
In Q3 2012, MSD reported worldwide sales of $11.5 billion. What was the contribution that emerging markets had? From an MSD perspective, emerging markets refer to every market outside North…
Pfizer completed the acquisition of Wyeth three years ago. How did the merge impact the Singaporean operations? As the result of the merge, Pfizer in Singapore has been able to…
Prior to joining AMRI you worked in diverse companies in Japan, like Dishman, Pfizer and Bayer. What attracted you to this company? The main reason is that Singapore has growing…
See our Cookie Privacy Policy Here
